Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03065790 · ClinicalTrials.gov registry record
Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- 1
- Enrollment target
NCT03065790 is a clinical trial that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1 participants.
The verdict
NCT03065790 was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.
Interventions
- DIAGNOSTIC_TEST 2-Deoxy-2-[18F]fluoro-D-glucose (FDG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2021-04-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03065790
The ClinicalTrials.gov registry entry for NCT03065790 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) is the first listed.
NCT03065790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03065790 about?
NCT03065790 is a clinical study titled "Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide". Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.
What is the current status of trial NCT03065790?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2017-02-06. Estimated completion is 2021-04-28.
What interventions are being tested in trial NCT03065790?
The interventions under investigation include: 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03065790?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.